Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism

Mona UCHIDA; Aki OHMI; Reina FUJIWARA; Kenjiro FUKUSHIMA; Akihiro DOI; Kazushi AZUMA; Hajime TSUJIMOTO

doi:10.1292/jvms.19-0605

Internal Medicine

Treatment with rivaroxaban and monitoring of coagulation profiles in two dogs with venous thromboembolism

Mona UCHIDA, Aki OHMI, Reina FUJIWARA, Kenjiro FUKUSHIMA, Akihiro DOI, Kazushi AZUMA, Hajime TSUJIMOTO

Author information

Mona UCHIDA
Department of Veterinary Clinical Pathobiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Aki OHMI
Veterinary Medical Center, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Reina FUJIWARA
Veterinary Medical Center, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Kenjiro FUKUSHIMA
Veterinary Medical Center, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Akihiro DOI
Veterinary Medical Center, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Kazushi AZUMA
Veterinary Medical Center, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan
Hajime TSUJIMOTO
Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan

Keywords: direct oral anticoagulant, heparin resistance, immune-mediated hemolytic anemia, thrombotic marker, venous thromboembolism

JOURNAL OPEN ACCESS

2020 Volume 82 Issue 9 Pages 1271-1276

DOI https://doi.org/10.1292/jvms.19-0605

Browse “Advance online publication” version

Details

Abstract

Two dogs with immune-mediated hemolytic anemia complicated with thromboembolism were presented. Both of the dogs were initially treated with immunosuppressive therapy in conjunction with dalteparin and clopidogrel. Although the immunosuppressive therapy was effective, peritoneal effusion due to thromboembolism was observed during the course of the disease in these dogs. After initiation of rivaroxaban treatment, peritoneal effusion decreased immediately in parallel with the normalization of D-dimer, antithrombin (AT), and thrombin-antithrombin complex (TAT). Hematochezia, cutaneous hemorrhage, and hematuria were observed as adverse events after administration of rivaroxaban in one case. Rivaroxaban was effective for the control of thromboembolism secondary to immune-mediated hemolytic anemia, and D-dimer, AT, and TAT were useful to monitor the status of thromboembolic disease in dogs.

Corresponding author

Register with J-STAGE for free!